CNTB stock forecast, quote, news & analysis
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD)... Show more
Why Connect Biopharma (CNTB) Stock Is Down -22% in the Last 30 Days
Key Takeaways
- Connect Biopharma (CNTB) shares fell roughly 22% over the last 30 days, from about $1.08 in late September to approximately $0.84, driven by mixed clinical data.
- The decline followed topline results from two Phase 2 Seabreeze STAT studies of rademikibart, its lead IL-4Rα antibody, which left key endpoints short of statistical significance.
- Several analysts lowered their price targets after the readouts, including Canaccord Genuity, Oppenheimer, and BTIG, while H.C. Wainwright maintained its Buy rating.
- Over the past quarter, the stock is down roughly 59%, reflecting a broader reset of expectations around rademikibart's registrational pathway.
- As a clinical-stage company, Connect Biopharma's near-term narrative now hinges on FDA alignment, its COPD dataset, and its cash runway into the second half of 2027.
- For additional detail, explore Price Targets, Earnings, and Forecast on dedicated pages.
- Investors can also explore Trending AI Robots to see how AI trading bots approach volatile biotech names.
Connect Biopharma (CNTB) Company Overview and Market Position
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on transforming care for inflammatory diseases, with an emphasis on asthma and chronic obstructive pulmonary disease (COPD). Its lead candidate, rademikibart, is a next-generation anti-interleukin-4-receptor-alpha (IL-4Rα) antibody designed to block inflammatory signaling driven by both IL-4 and IL-13 — the same pathway targeted by the blockbuster therapy Dupixent (dupilumab), marketed by Regeneron (REGN) and Sanofi (SNY).
Connect Biopharma is positioning rademikibart in the acute-care setting, targeting acute exacerbations of asthma and COPD where no IL-4Rα biologic is currently approved. The company has granted an exclusive license for rademikibart in Greater China to Simcere Pharmaceutical, under which it is eligible for up to approximately $110 million in remaining milestone payments plus tiered royalties. As a development-stage company, the stock is closely watched for clinical catalysts, regulatory progress, and its ability to fund late-stage trials.
Connect Biopharma (CNTB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CNTB declined approximately 22%, moving from a close near $1.08 in late September to roughly $0.84 in late October. The move was punctuated by elevated volatility and heavy trading volume, consistent with a binary, data-driven biotech repricing.
The longer view is steeper. Over the trailing quarter, the stock has fallen roughly 59%, from about $2.08 in late July to its current level. The shares reached a 52-week low during this stretch, with the broader trend reflecting a significant markdown in expectations around rademikibart following the release of mixed Phase 2 data in September.
What Drove CNTB Stock Price in the Last 30 Days
The dominant catalyst was a pair of Phase 2 clinical readouts. In mid-September, the company reported topline data from its Phase 2 Seabreeze STAT asthma trial. Rademikibart reduced the 28-day treatment-failure rate by approximately 66% versus placebo, but this primary endpoint missed statistical significance because the overall event rate was lower than projected. The study did meet a key secondary endpoint, showing a rapid, statistically significant improvement in lung function at day seven. The market nonetheless treated the mixed result as a setback, and shares fell sharply to a 52-week low.
Near the end of September, Connect Biopharma announced topline data from its Phase 2 Seabreeze STAT COPD trial. The study met its primary endpoint, showing an 81% reduction in treatment failures versus placebo, with no hospital or emergency-department readmissions in the treatment arm. However, a key secondary endpoint measuring lung function (FEV1) did not reach statistical significance, which dampened enthusiasm.
These readouts triggered a wave of analyst revisions. Canaccord Genuity lowered its price target, Oppenheimer cut its target from $8 to $5 while maintaining an Outperform rating, and BTIG reduced its target from $10 to $5 while pushing its projected market launch into 2030. H.C. Wainwright, by contrast, reiterated its Buy rating and $7 target.
What Drove CNTB Stock Performance Over the Last Quarter
The quarterly decline reflects a broader reassessment of rademikibart's commercial path. Earlier in 2026, the stock benefited from rising analyst coverage, including Buy initiations from Canaccord Genuity and Oppenheimer, and optimism that rademikibart could become a first-in-class treatment for acute asthma and COPD exacerbations. A March private placement of approximately $20.2 million at $3.25 per share extended the company's anticipated cash runway into the second half of 2027.
The September data, however, introduced meaningful uncertainty about the registrational endpoints the FDA will require for a Phase 3 program. Because the asthma primary endpoint and the COPD lung-function secondary endpoint both missed statistical significance, investors have reassessed the probability of near-term approval and the timeline to market, driving the sustained repricing over the quarter.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing and most relevant AI trading bots. While Tickeron provides hundreds of AI-driven bots that monitor thousands of tickers across the market, only the most relevant and best-performing strategies appear in this section. These bots vary by trading strategy, timeframe, and performance metrics, giving traders a range of approaches to consider. For investors tracking volatile clinical-stage names such as CNTB, the page offers a way to observe how automated, rule-based systems interpret price action and momentum signals.
CNTB Stock Forecast Drivers: What Investors Should Watch Next
Several factors will shape CNTB's outlook. The company has indicated plans to engage with the FDA to align on a registrational endpoint and a potential Phase 3 program, making regulatory feedback a pivotal near-term catalyst. Investors will also monitor additional COPD data and any follow-up analyses from the Seabreeze STAT studies.
Financial sustainability remains a key consideration. With a cash runway projected into the second half of 2027 and ongoing clinical-stage operating losses, future financing decisions and cash-burn trends will be closely watched. Upcoming quarterly results, analyst revisions, and institutional positioning may also influence sentiment. As with any clinical-stage biotech, the path forward depends heavily on trial outcomes and regulatory decisions, and outcomes remain uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CNTB's Indicator enters downward trend
The Aroon Indicator for CNTB entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 173 similar instances where the Aroon Indicator formed such a pattern. In 158 of the 173 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CNTB as a result. In 83 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CNTB's RSI Oscillator exited the oversold zone, 20 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CNTB just turned positive on October 07, 2026. Looking at past instances where CNTB's MACD turned positive, the stock continued to rise in 49 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Following a +11.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNTB advanced for three days, in 216 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
CNTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.715) is normal, around the industry mean (2.904). P/E Ratio (-0.615) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (24.272) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. CNTB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology